HK1198832A1 - Fn14 binding proteins and uses thereof fn14 - Google Patents

Fn14 binding proteins and uses thereof fn14

Info

Publication number
HK1198832A1
HK1198832A1 HK14112278.2A HK14112278A HK1198832A1 HK 1198832 A1 HK1198832 A1 HK 1198832A1 HK 14112278 A HK14112278 A HK 14112278A HK 1198832 A1 HK1198832 A1 HK 1198832A1
Authority
HK
Hong Kong
Prior art keywords
binding proteins
proteins
binding
Prior art date
Application number
HK14112278.2A
Other languages
English (en)
Chinese (zh)
Inventor
Nicholas Johannes Hoogenraad
Amelia Jane Johnston
John Silke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1198832A1 publication Critical patent/HK1198832A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
HK14112278.2A 2011-08-23 2014-12-05 Fn14 binding proteins and uses thereof fn14 HK1198832A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161526599P 2011-08-23 2011-08-23
PCT/AU2012/000989 WO2013026099A1 (fr) 2011-08-23 2012-08-23 Protéines de liaison à fn14 et leurs utilisations

Publications (1)

Publication Number Publication Date
HK1198832A1 true HK1198832A1 (en) 2015-06-12

Family

ID=47745774

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112278.2A HK1198832A1 (en) 2011-08-23 2014-12-05 Fn14 binding proteins and uses thereof fn14

Country Status (9)

Country Link
US (6) US9006397B2 (fr)
EP (1) EP2748203B1 (fr)
JP (1) JP2014529597A (fr)
AU (1) AU2012300191B2 (fr)
CA (1) CA2845946A1 (fr)
ES (1) ES2748021T3 (fr)
HK (1) HK1198832A1 (fr)
SG (1) SG2014010334A (fr)
WO (1) WO2013026099A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2845946A1 (fr) 2011-08-23 2013-02-28 Transbio Ltd Proteines de liaison a fn14 et leurs utilisations
TW201534623A (zh) * 2013-06-14 2015-09-16 Bayer Pharma AG 抗－ｔｗｅａｋｒ抗體及其用途
US9238034B2 (en) 2013-07-09 2016-01-19 The Translational Genomics Research Institute FN14 antagonists and therapeutic uses thereof
US9797882B2 (en) 2013-07-09 2017-10-24 The Translational Genomics Research Institute Method of screening for a compound for inhibitory activity of FN14-tweak interaction
US10584175B2 (en) 2014-10-23 2020-03-10 La Trobe University FN14-binding proteins and uses thereof
SG11202104463YA (en) 2018-10-31 2021-05-28 Astellas Pharma Inc Anti-human fn14 antibody
US20220289857A1 (en) * 2018-12-20 2022-09-15 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
WO2021214905A1 (fr) * 2020-04-22 2021-10-28 アステラス製薬株式会社 Composition pharmaceutique et procédé de prévention ou de traitement du cancer par utilisation conjointe d'un anticorps anti-fn14 humain et d'un inhibiteur de point de contrôle immunitaire
EP3984547A1 (fr) * 2020-10-14 2022-04-20 Universitat Pompeu Fabra Peptides pour le traitement du cancer
MX2023008372A (es) 2021-01-13 2023-07-26 Astellas Pharma Inc Anticuerpo multiespecifico que se une a actriia, actriib y fn14.
WO2022155705A1 (fr) * 2021-01-20 2022-07-28 La Trobe University Protéines de liaison à fn14 humanisées et leurs utilisations
WO2023062848A1 (fr) * 2021-10-14 2023-04-20 Astellas Pharma Inc. Composition pharmaceutique comprenant un anticorps fnl4 anti-humain ou un fragment de liaison à l'antigène de celui-ci pour la prévention ou le traitement du cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495086B2 (en) * 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
NZ548701A (en) * 2002-04-09 2008-03-28 Biogen Idec Inc Methods for treating tweak-related conditions
EP2545938A1 (fr) * 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Utilisation thérapeutique dýanticorps de récepteur anti-TWEAK
BRPI0912198A2 (pt) * 2008-05-15 2019-09-24 Biogen Idec Inc anticorpos anti-fn14 e usos dos mesmos
CA2845946A1 (fr) 2011-08-23 2013-02-28 Transbio Ltd Proteines de liaison a fn14 et leurs utilisations
US10584175B2 (en) * 2014-10-23 2020-03-10 La Trobe University FN14-binding proteins and uses thereof

Also Published As

Publication number Publication date
US20150218278A1 (en) 2015-08-06
US20170029519A1 (en) 2017-02-02
EP2748203A1 (fr) 2014-07-02
AU2012300191A1 (en) 2013-04-04
SG2014010334A (en) 2014-06-27
JP2014529597A (ja) 2014-11-13
US20200239586A1 (en) 2020-07-30
ES2748021T3 (es) 2020-03-12
AU2012300191B2 (en) 2014-04-17
US20180057599A1 (en) 2018-03-01
US20130273036A1 (en) 2013-10-17
US20200002430A1 (en) 2020-01-02
CA2845946A1 (fr) 2013-02-28
US10287359B2 (en) 2019-05-14
EP2748203B1 (fr) 2019-05-15
WO2013026099A1 (fr) 2013-02-28
US9006397B2 (en) 2015-04-14
EP2748203A4 (fr) 2015-04-22

Similar Documents

Publication Publication Date Title
HK1217511A1 (zh) 包含 結構域的結合蛋白
HK1216257A1 (zh) 催乳素受體結合蛋白及其用途
IL230918A0 (en) Modified proteins and peptides
HK1200871A1 (en) Modified dna-binding proteins and uses thereof dna-
HK1198832A1 (en) Fn14 binding proteins and uses thereof fn14
EP2654792A4 (fr) Protéines de liaison à une demi-immunoglobuline et leurs utilisations
IL222323A0 (en) Tnf - alpha binding proteins
SG11201401649VA (en) Albumin binding antibodies and binding fragments thereof
EP2681239B8 (fr) Protéines de liaison à un antigène
SG10201401681PA (en) Novel antigen binding proteins
IL222961A0 (en) Novel dna-dinding proteins and uses thereof
ZA201304905B (en) TNF-a BINDING PROTEINS
HK1202444A1 (en) Il-1 binding proteins il-1
ZA201205624B (en) Cd127 binding proteins
ZA201400562B (en) Axmi205 variant proteins and methods for their use
IL226157A0 (en) Antigen binding proteins
EP2558500A4 (fr) Protéines qui se lient à pi16 et leurs utilisations
EP2793918A4 (fr) Peptides de liaison à hdc-sign
EP2771689A4 (fr) Peptides usp2a et anticorps
GB201121233D0 (en) Modified proteins and peptides
GB201121226D0 (en) Modified proteins and peptides
GB201121236D0 (en) Proteins and peptides